Everyday clinical question to Nick James
⭕️Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) are candidates for a combination of ADT, docetaxel, and AR pathway inhibitors?
⭕️The selection for this potent triplet systemic therapy requires careful

M.R. Smith eloquently pointed out the predictive and prognostic in mCSPC
#Apccc24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Thomas Zilli Daniel Castellano Piet Ost Emre Yekedüz Dra. María Natalia Gandur Quiroga Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji Neeraj Agarwal, MD, FASCO Maite Bourlon Neha Vapiwala Andrey Soares

What are the recommended imaging modalities in mCSPC? Michael Morris
⭕️ Unclear what is the best imaging algorithm !
#Apccc24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Thomas Zilli Daniel Castellano Piet Ost Emre Yekedüz Dra. María Natalia Gandur Quiroga Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji Neeraj Agarwal, MD, FASCO

In which patient with metachronus low vol mCSPC do you recommend “total therapy “ clinical relevant question! Thomas Zilli

#Apccc24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Piet Ost Daniel Castellano Piet Ost Emre Yekedüz Dra. María Natalia Gandur Quiroga Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji Neeraj Agarwal, MD, FASCO

OUR MOST SINCERE CONGRATULATIONS TO
Advanced Prostate Cancer Consensus Conference 🇨🇭silke gillessen & aurelius omlin

OVER 1⃣,1⃣0⃣0⃣Participants at #APCCC24 discussing the most important topics around #ProstateCancer

Join the Conversation through the hashtag #APCCC24

Neeraj Agarwal, MD, FASCO Ravindran Kanesvaran Simon C

Debate time at Advanced Prostate Cancer Consensus Conference
Piet Ost ☢️ Local control is NOT the problem with RT! Distant met remain main issue!
☢️more risk, more systemic therapy not more intensive local Rx.
#Apccc24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Thomas Zilli Daniel Castellano Piet Ost

🚀 #APCCC24 Session 1: High-risk & locally advanced prostate cancer. Chairs Neha Vapiwala & Neal Shore will explore the relevance of digital rectal exams in the era of MRI and next-gen imaging. Join the conversation! 💡
OncoAlert Advanced Prostate Cancer Consensus Conference
🔍 Insightful talk by

🌟 #APCCC24 kicks off TODAY, April 25th! Don’t miss the APCCC 2024 opening session featuring silke gillessen and aurelius omlin
OncoAlert  Advanced Prostate Cancer Consensus Conference 
🔍 David Matheson will delve into what's important from a patient's perspective. Connect with us and leading oncology experts!

Fantastic start of
#APCCC perfect also in virtual format for the ones that couldn’t make it to #Lugano
#Apccc24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Thomas Zilli Derya Tilki, MD Daniel Castellano Rana McKay Piet Ost Dra. María Natalia Gandur Quiroga Deborah Mukherji Neeraj Agarwal, MD, FASCO Ravindran Kanesvaran

PSMA is everywhere! More RLT to come!
Captivating presentation at APCCC! 💡 #inspirational Ken Herrmann
#Apccc24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Thomas Zilli Derya Tilki, MD Daniel Castellano Irbaz Riaz MD,MS,MBI,PhD Piet Ost Dra. María Natalia Gandur Quiroga Deborah Mukherji Andrew Armstrong prof. Stefano Fanti

👏🏼👏🏼🙌 #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference onkowissen European Association of Urology (EAU)

Siamo arrivati a Lugano🇨🇭
And what an office view ⛵️

#APCCC24 is coming to us tomorrow and OncoAlert 🚨is beyond proud to be working with Advanced Prostate Cancer Consensus Conference in the coverage of this great conference.

Look forward to some amazing discussions and very excited to be doing that in

We can't wait for tomorrow's Translational Prostate Cancer Symposium, the prelude to the eagerly awaited #APCCC24 !

Join us on April 24th in Lugano.

🔬 Session Breakdown:
Welcome And Opening Remarks by Silke Gillessen silke gillessen and Jean-Philippe Theurillat Jean-Philippe Theurillat.

Cannot agree more ! ADCs need their target to bind -> no target no action.

It is an exciting time for translational research in this field. Pathologists need to be involved as we will need to test for many indications soon likely!

oncology!

Markus Eckstein Paolo Tarantino

With less than a week until #APCCC24 begins, we’re highlighting again the crucial sessions on systemic therapy side effects and metastatic CRPC management.

Whether you join us in the city of Lugano🇨🇭or tune in virtually, these discussions are pivotal for anyone interested in

🌟 Just 1 Week to Go Until #APCCC24 ! 🌟

🚀 Are you ready for the most anticipated oncology conference of the year? APCCC 2024 kicks off next week, April 25-27, in the stunning city of Lugano🇨🇭!

With our hybrid format, don't miss your chance to be part of this transformative

Happy to share our mini-review about current evidence on biomarkers for predicting response to enfortumab vedotin for metastatic urinary tract cancer (mUC) Markus Eckstein Eur Urol Focus

➡️ recent literature suggests an overestimation of targetable NECTIN4 expression prevalence

💫🌟 NCCN 2024 Prostate Cancer Guidelines Update 🌟💫
Zach Klaassen Rashid K. Sayyid
UroToday.com OncoAlert Advanced Prostate Cancer Consensus Conference urotoday.com/video-lectures…
🔹️ Major updates focus on the management of progressive M0 CSPC post-maximal pelvic therapy. 
🔹️ Introduction of enzalutamide, with or

Want more information on treatment considerations and managing immunotherapy-related adverse effects for patients with #BladderCancer ? Axel S. Merseburger Shilpa Gupta Watch here: onclive.com/view/bladder-c…

Apalutamide + ADT in clinical subgroups of patients with #mCSPC : A subgroup analysis of the randomized clinical #TITAN study. #BeyondTheAbstract with Axel S. Merseburger Universitätsklinikum Schleswig-Holstein > bit.ly/3T49Bq9